{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:23:23Z","timestamp":1791843803191,"version":"4.3.4"},"reference-count":37,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"unspecified","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pionyr Immunotherapeutics","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Novel treatment options are required in patients with platinum-resistant ovarian cancer (PROC). Myeloid-derived suppressor cells promote a hostile tumor microenvironment and are associated with worse clinical outcomes in PROC. We evaluated the safety and preliminary efficacy of PY159, an agonist antibody to Triggering receptor expressed on myeloid cells-1 (TREM1) that reprograms immunosuppressive intratumoral myeloid cells, and PY314, an antagonist antibody to Triggering receptor expressed on myeloid cells-2 (TREM2) that depletes tumor-associated macrophages, as single agents and in combination with pembrolizumab in subjects with PROC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PY159 and PY314 were individually evaluated in patients with PROC. Patients were treated with monotherapy (PY159 3\u2009mg\/kg or PY314 10\u2009mg\/kg), based on the recommended dose for expansion derived from the phase 1a studies. At the time of first progression, patients could continue study drug and crossover to combination therapy with pembrolizumab (200\u2009mg) every 3 weeks at the discretion of the investigator. Disease assessment by Response Evaluation Criteria in Solid Tumor version 1.1 was performed every 6 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>17 patients were enrolled in the PY159 study (median age 67, range 22\u201377; median prior therapies 6, range 2\u201318) and 16 patients in PY314 (median age 65.5, range 49\u201381; median prior therapies 4, range 2\u201310). 7 patients in PY159 and 8 patients in PY314 crossed over to combination therapy. Safety events included the following: treatment-related adverse events occurred in 15 patients (88.2%) in PY159 and 9 patients (56.3%) in PY314. Infusion-related reactions occurred in 6 patients (35.3%) in PY159 and 3 patients (18.8%) in PY314. Immune-related adverse events occurred in 13 patients (76.5%) in PY159 (arthralgias) and 1 patient (6.3%) in PY314 (diarrhea). Serious adverse events occurred in 6 patients (36.3%) in PY159 (1 related) and 12 patients (75%) in PY314 (all unrelated). The best radiographic response in PY159 was stable disease in 8\/16 patients (50%; median 16 weeks, range 9\u201333), and in PY314, it was stable disease in 8\/16 patients (50%; median 12 weeks, range 6\u201336). Median PFS was 2.76 months and 2.69 months in PY159 and PY314, respectively. There were no responses in the crossover arm.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Both PY159 and PY314 were well tolerated, with an acceptable safety profile, as both single agents and in combination with pembrolizumab. Both agents warrant further investigation in heavily pretreated PROC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-010959","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T08:26:06Z","timestamp":1741854366000},"page":"e010959","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-1647","authenticated-orcid":false,"given":"Oladapo O","family":"Yeku","sequence":"first","affiliation":[{"name":"Medicine\/Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Barve","sequence":"additional","affiliation":[{"name":"Mary Crowley Cancer Research, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston W","family":"Tan","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Jackson, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Wang","sequence":"additional","affiliation":[{"name":"Drug Development Unit, Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Patnaik","sequence":"additional","affiliation":[{"name":"The START Center for Cancer Research, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[{"name":"Yale University Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3992-8610","authenticated-orcid":false,"given":"Debra L","family":"Richardson","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, The University of Oklahoma Stephenson Cancer Center, Oklahoma City, Oklahoma, USA"},{"name":"Sarah Cannon Research Institute, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[{"name":"Medical Oncology\/TSET Phase 1 Program, Stephenson Cancer Center\/Sarah Cannon Research Institute, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K","family":"Lynam","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[{"name":"HonorHealth, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joleen","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Allina Health Cancer Institute, Minneapolis, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaani","family":"Kummar","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-7405","authenticated-orcid":false,"given":"Christos","family":"Kyriakopoulos","sequence":"additional","affiliation":[{"name":"Medicine, Hematology\/Oncology, University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[{"name":"University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Chamberlain","sequence":"additional","affiliation":[{"name":"Pionyr Immunotherapeutics, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Winer","sequence":"additional","affiliation":[{"name":"Wayne State University and Karmanos Cancer Center, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2026052722304273000_13.3.e010959.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026052722304273000_13.3.e010959.2","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014544121"},{"key":"2026052722304273000_13.3.e010959.3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ygyno.2016.05.020","article-title":"Primary and acquired platinum-resistance among women with high grade serous ovarian cancer","volume":"142","author":"Slaughter","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2026052722304273000_13.3.e010959.4","first-page":"1397","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026052722304273000_13.3.e010959.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169"},{"key":"2026052722304273000_13.3.e010959.6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14215332","article-title":"Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints","volume":"14","author":"Hudry","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026052722304273000_13.3.e010959.7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310859","article-title":"Current Understanding on Why Ovarian Cancer Is Resistant to Immune Checkpoint Inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026052722304273000_13.3.e010959.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01977","article-title":"Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression","volume":"9","author":"Awad","year":"2018","journal-title":"Front Immunol"},{"key":"2026052722304273000_13.3.e010959.9","doi-asserted-by":"publisher","DOI":"10.1002\/path.1027"},{"key":"2026052722304273000_13.3.e010959.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.02.009"},{"key":"2026052722304273000_13.3.e010959.11","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12976"},{"key":"2026052722304273000_13.3.e010959.12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102401","article-title":"The Crowded Crosstalk between Cancer Cells and Stromal Microenvironment in Gynecological Malignancies: Biological Pathways and Therapeutic Implication","volume":"20","author":"De Nola","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026052722304273000_13.3.e010959.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6"},{"key":"2026052722304273000_13.3.e010959.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01611","article-title":"Tuning the Tumor Myeloid Microenvironment to Fight Cancer","volume":"10","author":"Jahchan","year":"2019","journal-title":"Front Immunol"},{"key":"2026052722304273000_13.3.e010959.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.5.3520"},{"key":"2026052722304273000_13.3.e010959.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2009.01.009"},{"key":"2026052722304273000_13.3.e010959.17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094241","article-title":"TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer","volume":"9","author":"Yuan","year":"2014","journal-title":"PLoS ONE"},{"key":"2026052722304273000_13.3.e010959.18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.677286"},{"key":"2026052722304273000_13.3.e010959.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109844"},{"key":"2026052722304273000_13.3.e010959.20","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10060943","article-title":"Exploring the Impact of TREM2 in Tumor-Associated Macrophages","volume":"10","author":"Khantakova","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"2026052722304273000_13.3.e010959.21","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194635","article-title":"TREM2 Is Associated with Advanced Stages and Inferior Prognosis in Oral Squamous Cell Carcinoma","volume":"14","author":"Struckmeier","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026052722304273000_13.3.e010959.22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1089266","article-title":"TREM2 is associated with tumor immunity and implies poor prognosis in glioma","volume":"13","author":"Yu","year":"2022","journal-title":"Front Immunol"},{"key":"2026052722304273000_13.3.e010959.23","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2023.41.16_suppl.2523","article-title":"A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1)","volume":"41","author":"Winer","year":"2023","journal-title":"JCO"},{"key":"2026052722304273000_13.3.e010959.24","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1200\/JCO.2022.40.16_suppl.2648","article-title":"A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody","volume":"40","author":"Patnaik","year":"2022","journal-title":"JCO"},{"key":"2026052722304273000_13.3.e010959.25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093125","article-title":"The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors","volume":"21","author":"Baci","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026052722304273000_13.3.e010959.26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005968","article-title":"Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma","volume":"11","author":"Truxova","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052722304273000_13.3.e010959.27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2217\/fon-2023-0246","article-title":"ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer","volume":"19","author":"Herzog","year":"2023","journal-title":"Future Oncol"},{"key":"2026052722304273000_13.3.e010959.28","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/cncr.35126","article-title":"Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer","volume":"130","author":"Hinchcliff","year":"2024","journal-title":"Cancer"},{"key":"2026052722304273000_13.3.e010959.29","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004812"},{"key":"2026052722304273000_13.3.e010959.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00529"},{"key":"2026052722304273000_13.3.e010959.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00342-9"},{"key":"2026052722304273000_13.3.e010959.32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00306"},{"key":"2026052722304273000_13.3.e010959.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00216-3"},{"key":"2026052722304273000_13.3.e010959.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.10.005"},{"key":"2026052722304273000_13.3.e010959.35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaoncol.2022.5228","article-title":"Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026052722304273000_13.3.e010959.36","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1007\/s12013-024-01377-8","article-title":"Pharmacological Inhibition or Silencing of TREM1 Restrains HCC Cell Metastasis by Inactivating TLR\/PI3K\/AKT Signaling","volume":"82","author":"Ren","year":"2024","journal-title":"Cell Biochem Biophys"},{"key":"2026052722304273000_13.3.e010959.37","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1158\/2159-8290.CD-24-0018","article-title":"TREM2-Expressing Multinucleated Giant Macrophages Are a Biomarker of Good Prognosis in Head and Neck Squamous Cell Carcinoma","volume":"14","author":"Gessain","year":"2024","journal-title":"Cancer Discov"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:31:16Z","timestamp":1779946276000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,13]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/jitc-2024-010959"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010959","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}